TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02480114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Undergo oral care and pain management education session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo oral care and pain management education session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO
Study: NCT01032408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Begrivac®
Description: 15 ug of HA antigen; non-adjuvanted; trivalent
Study: NCT02480114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Therapy
Description: Receive usual oral health care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Therapy
Description: Receive usual oral health care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Acetaminophen
Description: Analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen
Description: Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: Analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen
Description: Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Transdermal Analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Transdermal Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: NSAID Analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID Analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magic Mouthwash
Description: Oral Solution to treat mucositis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magic Mouthwash
Description: Oral Solution to treat mucositis
Study: NCT00437957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 Mg/m2/day for all Cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy
Description: Concurrently with Temozolomide and VPA
Study: NCT03334981

Intervention type: PROCEDURE
Intervention: Concentrations in Meconium of Buprenorphine and Methadone
Description: buprenorphine or methadone concentration measurement
Study: NCT01317160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Description: 6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
Study: NCT01017042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine tablets
Description: colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
Study: NCT02682485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro, metronidazole, neomycin combo
Description: During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Endoscopic Surveillance
Description: Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Serial Endoscopic Surveillance
Description: Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
Study: NCT02505191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's wort prolonged-release tablet 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: St. John's wort film coated tablets 250 mg
Study: NCT03954275

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00826995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
Study: NCT01995825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand lamotrigine
Description: Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand lamotrigine
Description: Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
Study: NCT00826995

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
Study: NCT03139331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
Study: NCT03911531

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Exome Sequencing
Description: Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Exome Sequencing
Description: Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Genome Sequencing
Description: Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
Study: NCT03882866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-printed non-coplanar template
Description: 3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D-printed coplanar template
Description: 3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
Study: NCT01467024

Intervention type: OTHER
Intervention: CDPHL Algorithm
Description: Supplemental testing algorithm performed by the CDPHL.

Intervention type: OTHER
Intervention: CDPHL Algorithm
Description: Supplemental testing algorithm performed by the CDPHL.

Intervention type: OTHER
Intervention: CDPHL Algorithm
Description: Supplemental testing algorithm performed by the CDPHL.
Study: NCT01847872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV ID Needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV ID Device
Study: NCT01135004

Intervention type: PROCEDURE
Intervention: Thoracoscopic bullectomy
Description: Thoracoscopic wedge resection of the diseased lung
Study: NCT02289521

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation).
Study: NCT02074761

Intervention type: DEVICE
Intervention: SImmetry
Description: The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.
Study: NCT02249260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Group-based high-intensity aerobic interval training and lifestyle counseling
Study: NCT00646191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg weekly through Week 48 (OL Week 12 - 48)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
Study: NCT03463044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04573153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Metabolic cofactor supplementation
Description: Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine + Sorbitol
Description: Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
Study: NCT04519216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telesimulation
Description: Telesimulation educational intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telesimulation
Description: Telesimulation educational intervention
Study: NCT04603313

Intervention type: OTHER
Intervention: tele-advice system
Description: The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
Study: NCT04017624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Truck with stipend
Description: Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location.
Study: NCT03911531

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Genome Sequencing
Description: Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
Study: NCT03972046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-Vec)
Description: Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib (BRAF Inhibitor)
Description: Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
Study: NCT03251235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Study: NCT01667835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: 12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
Study: NCT03776812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant, 100mg QD
Description: Relacorilant is supplied as capsules for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel, 80mg/m^2
Description: Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel, 80mg/m^2
Description: Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel, 100mg/m^2
Description: Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant, 150mg QD
Description: Relacorilant is supplied as capsules for oral dosing
Study: NCT01156025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV550
Description: Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
Study: NCT02293967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study: NCT00949923

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tea capsule
Description: 3 tea capsules daily for 3 weeks
Study: NCT02557451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of gas

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injections of an antiangiogenic
Study: NCT04017624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE screening and referral
Description: The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
Study: NCT02203942

Intervention type: OTHER
Intervention: NAAT testing
Description: comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
Study: NCT01995825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic lamotrigine
Description: Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic lamotrigine
Description: Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
Study: NCT04988646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 MG
Description: Administered with 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 MG
Description: Administered with 240 mL of water
Study: NCT02382770

Intervention type: PROCEDURE
Intervention: Open abdomen procedure
Description: Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
Study: NCT01925300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab
Study: NCT04988646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zovirax 200 MG Tablet
Description: Administered with 240 mL of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zovirax 400 MG Tablet
Description: Administered with 240 mL of water
Study: NCT03036046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 with fluconazole low dose
Description: adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 with fluconazole high dose
Description: adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 with posaconazole
Description: adverse events
Study: NCT02951728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab